The forecasted treatment success rate for HIV-positive tuberculosis in China shows a decline from 2024 to 2028, starting at 56 in 2024 and decreasing to 53 by 2028. Comparatively, the success rate in 2023 was higher than the forecasted values, indicating a downward trend in effectiveness over these years. The year-on-year reduction is steady, with slightly decreasing percentages of success, suggestive of potential challenges in maintaining treatment efficacy. The five-year compound annual growth rate (CAGR) highlights this decrease, averaging a consistent drop each year.
Future trends to watch include advancements in medical treatments that could reverse this decline, policy changes focusing on integrated care for co-infections, and potential increases in funding or resources dedicated to HIV and tuberculosis. Monitoring technological innovations and public health initiatives will be critical in affecting future treatment outcomes.
